Cargando…

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has potentiated the survival of certain breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Bi, Chen, Xiaosong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034161/
https://www.ncbi.nlm.nih.gov/pubmed/36969235
http://dx.doi.org/10.3389/fimmu.2023.1164514
_version_ 1784911150633189376
author Lian, Bi
Chen, Xiaosong
Shen, Kunwei
author_facet Lian, Bi
Chen, Xiaosong
Shen, Kunwei
author_sort Lian, Bi
collection PubMed
description Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has potentiated the survival of certain breast cancer patients; however, primary resistance or acquired resistance attenuate the therapeutic outcomes. Histone acetyltransferases induce histone acetylation on lysine residues, which can be reversed by histone deacetylases (HDACs). Dysregulation of HDACs via mutation and abnormal expression contributes to tumorigenesis and tumor progression. Numerous HDAC inhibitors have been developed and exhibited the potent anti-tumor activity in a variety of cancers, including breast cancer. HDAC inhibitors ameliorated immunotherapeutic efficacy in cancer patients. In this review, we discuss the anti-tumor activity of HDAC inhibitors in breast cancer, including dacinostat, belinostat, abexinostat, mocetinotat, panobinostat, romidepsin, entinostat, vorinostat, pracinostat, tubastatin A, trichostatin A, and tucidinostat. Moreover, we uncover the mechanisms of HDAC inhibitors in improving immunotherapy in breast cancer. Furthermore, we highlight that HDAC inhibitors might be potent agents to potentiate immunotherapy in breast cancer.
format Online
Article
Text
id pubmed-10034161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100341612023-03-24 Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer Lian, Bi Chen, Xiaosong Shen, Kunwei Front Immunol Immunology Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has potentiated the survival of certain breast cancer patients; however, primary resistance or acquired resistance attenuate the therapeutic outcomes. Histone acetyltransferases induce histone acetylation on lysine residues, which can be reversed by histone deacetylases (HDACs). Dysregulation of HDACs via mutation and abnormal expression contributes to tumorigenesis and tumor progression. Numerous HDAC inhibitors have been developed and exhibited the potent anti-tumor activity in a variety of cancers, including breast cancer. HDAC inhibitors ameliorated immunotherapeutic efficacy in cancer patients. In this review, we discuss the anti-tumor activity of HDAC inhibitors in breast cancer, including dacinostat, belinostat, abexinostat, mocetinotat, panobinostat, romidepsin, entinostat, vorinostat, pracinostat, tubastatin A, trichostatin A, and tucidinostat. Moreover, we uncover the mechanisms of HDAC inhibitors in improving immunotherapy in breast cancer. Furthermore, we highlight that HDAC inhibitors might be potent agents to potentiate immunotherapy in breast cancer. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10034161/ /pubmed/36969235 http://dx.doi.org/10.3389/fimmu.2023.1164514 Text en Copyright © 2023 Lian, Chen and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lian, Bi
Chen, Xiaosong
Shen, Kunwei
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title_full Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title_fullStr Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title_full_unstemmed Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title_short Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
title_sort inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034161/
https://www.ncbi.nlm.nih.gov/pubmed/36969235
http://dx.doi.org/10.3389/fimmu.2023.1164514
work_keys_str_mv AT lianbi inhibitionofhistonedeacetylasesattenuatestumorprogressionandimprovesimmunotherapyinbreastcancer
AT chenxiaosong inhibitionofhistonedeacetylasesattenuatestumorprogressionandimprovesimmunotherapyinbreastcancer
AT shenkunwei inhibitionofhistonedeacetylasesattenuatestumorprogressionandimprovesimmunotherapyinbreastcancer